1. Classification and Chemical Overview

Oxazepam is a short-to-intermediate-acting 3-hydroxy benzodiazepine derivative. It is a active metabolite of diazepam, prazepam, and temazepam. Under the Anatomical Therapeutic Chemical (ATC) classification system, oxazepam is indexed under N05BA04.

Chemically designated as 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, oxazepam features a hydroxyl group at position 3 of the benzodiazepine ring. In healthcare systems across Europe, Australasia, and North America, oxazepam is classified as a Controlled Substance (e.g., Schedule 4 Controlled Drug) and is available strictly as a Prescription Only Medicine (POM). The 50 mg tablet/capsule formulation represents a high single-dose strength.

2. Mechanism of Action and Pharmacodynamics

Oxazepam functions as a positive allosteric modulator at central nervous system FRENTEA​ receptor complexes. It binds to the specific benzodiazepine site located at the interface between the $\alpha$ y γ2​ subunits of the ionotropic FRENTEA​ receptor.

Binding enhances the affinity of $\gamma$-aminobutyric acid (GABA) for its receptor, increasing the frequency of chloride channel opening. The resulting influx of chloride ions hyperpolarises the postsynaptic neuronal membrane, inhibiting action potential firing across the limbic system, thalamus, and cerebral cortex.

Oxazepam demonstrates anxiolytic, sedative, muscle-relaxant, and anticonvulsant properties. Compared to longer-acting benzodiazepines, oxazepam exhibits slower receptor binding kinetics and a slower onset of action.

3. Approved Clinical Indications and Therapeutic Scope

Licensing for oral oxazepam 50 mg includes:

• Severe Acute Anxiety: Management of severe, disabling anxiety states or acute agitation (typically 15 mg to 30 mg, scaling up to 50 mg per dose in severe inpatient or psychiatric cases, up to 3–4 times daily).

• Acute Alcohol Withdrawal: Treatment of acute withdrawal symptoms, including motor agitation, severe anxiety, and impending delirium tremens (15 mg to 50 mg taken 3 to 4 times daily).

• Severe Insomnia Associated with Anxiety: Short-term management of severe sleep onset or maintenance insomnia secondary to acute anxiety (15 mg to 50 mg administered 1 hour before bedtime).

Clinical Usage & Duration Guidance: Prescribing must be restricted to short-term course durations (2 to 4 weeks maximum) to mitigate risks of pharmacological tolerance, physical dependence, and addiction. The 50 mg strength is reserved for severe acute clinical scenarios and is inappropriate as an initial starting dose in elderly or debilitated patients (where 7.5 mg to 10 mg is recommended).

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Oxazepam is absorbed relatively slowly from the gastrointestinal tract compared to other benzodiazepines. Peak plasma concentrations (Tmax​) are achieved in 1 to 4 hours following oral administration. Absolute oral bioavailability is approximately 92% to 97%.

• Distribution: Highly lipophilic with wide tissue distribution. Volume of distribution (Vd​) ranges from 0.6 to 1.0 L/kg. Plasma protein binding is approximately 86% to 88% (bound primarily to human serum albumin).

• Biotransformation: Unlike diazepam or chlordiazepoxide, oxazepam undergoes direct Phase II hepatic metabolism without requiring Phase I Cytochrome P450 oxidation. It is directly conjugated with glucuronic acid in the liver to form the inactive metabolite oxazepam glucuronide.

• Clinical Significance of Metabolism: Because it bypasses CYP450 oxidation pathways, oxazepam’s metabolic clearance is remarkably preserved in elderly patients, individuals with mild-to-moderate hepatic impairment (e.g., cirrhosis), and those taking CYP enzyme inhibitor drugs.

• Elimination: Oxazepam glucuronide is excreted predominantly via the kidneys in urine. The elimination half-life (t1/2​) of parent oxazepam is 4 to 15 hours (mean $\approx 8\text{–}10\text{ hours}$), placing it firmly in the short-to-intermediate duration class.

5. Physiological Effects and Adverse Event Spectrum

Oxazepam depresses central nervous system excitability, leading to reduced anxiety, mild-to-moderate sedation, elevated seizure threshold, and muscle relaxation.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Drowsiness, daytime sedation, fatigue, ataxia, lightheadedness.

• Common ($\ge 1/100$ to $<1/10$): Confusion, muscle weakness, dizziness, headache, slurred speech (dysarthria), memory impairment / anterograde amnesia, visual disturbances.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Hypersensitivity reactions, changes in libido, gastrointestinal disturbance (nausea, constipation), blood dyscrasias, skin rashes.

• Rare (<1/1,000): Respiratory depression, hypotension, hepatic dysfunction/jaundice, paradoxical reactions (including acute excitement, agitation, hostility, hallucinations, and sleep disturbances).

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to oxazepam or other benzodiazepines.

• Acute severe respiratory insufficiency or respiratory depression.

• Severe sleep apnoea syndrome.

• Myasthenia gravis.

• Acute narrow-angle glaucoma.

• Severe phobic or obsessional states; chronic psychosis.

Key Drug Interactions

• CNS Depressants & Alcohol: Concomitant administration with opioids, other sedatives, hypnotics, antipsychotics, or alcohol markedly potentiates central nervous system depression, elevating risks of profound sedation, respiratory depression, coma, and death.

• Probenecid: Inhibits hepatic glucuronidation, increasing oxazepam plasma levels and prolonging its duration of action.

• Opioids: Concurrent use must be restricted exclusively to situations where alternative treatment options are inadequate, using the lowest effective doses for the shortest duration.

Clinical Precautions and Monitoring

• Dependence & Rebound/Withdrawal: Physical and psychological dependence can develop rapidly. Abrupt cessation of a 50 mg regimen can trigger severe rebound anxiety, tremors, psychosis, delirium, and life-threatening withdrawal seizures. Dosages must be gradually tapered.

• Elderly Patients: Elderly individuals display heightened pharmacodynamic sensitivity to benzodiazepines. High doses (such as 50 mg) carry substantial risks of severe confusion, over-sedation, impaired coordination, and traumatic falls.

• Driving and Operating Machinery: Oxazepam 50 mg causes significant impairment of cognitive and motor performance. Patients must not drive or operate complex machinery during treatment.